{"id":"aptensio-xr","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Nervousness"},{"rate":"5","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":{"setId":"5adedc01-ebf0-11e3-ac10-0800200c9a66","title":"APTENSIO XR (METHYLPHENIDATE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [RHODES PHARMACEUTICALS L.P.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, increasing their concentration in the synaptic cleft. The extended-release formulation provides sustained drug delivery over 12 hours, allowing once-daily dosing. This mechanism enhances executive function, attention span, and impulse control in patients with attention-deficit/hyperactivity disorder.","oneSentence":"Aptensio XR is an extended-release formulation of methylphenidate that increases dopamine and norepinephrine activity in the central nervous system to improve attention and reduce hyperactivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:40.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"}]},"trialDetails":[{"nctId":"NCT07300956","phase":"PHASE4","title":"Treating Young Children With Attention Deficit Hyperactivity Disorder","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-02","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":370},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT04419272","phase":"PHASE4","title":"Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-08-14","conditions":"Epilepsy","enrollment":226},{"nctId":"NCT02683265","phase":"PHASE4","title":"A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":158},{"nctId":"NCT02470234","phase":"PHASE4","title":"Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":10},{"nctId":"NCT02677519","phase":"PHASE4","title":"A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD","status":"UNKNOWN","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20250923","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20190614","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20170104","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20231013","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20210625","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20150417","type":"ORIG","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"},{"date":"20150915","type":"SUPPL","sponsor":"RHODES PHARMS","applicationNumber":"NDA205831"}],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Methylphenidate Extended Release","methylphenidate, extended release"],"phase":"marketed","status":"active","brandName":"Aptensio XR","genericName":"Aptensio XR","companyName":"Rhodes Pharmaceuticals, L.P.","companyId":"rhodes-pharmaceuticals-l-p","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aptensio XR is a small molecule medication used to treat Attention Deficit Disorder With Hyperactivity, Attention-Deficit/Hyperactivity Disorder (ADHD), and Autism Spectrum Disorder. It is an extended-release formulation of methylphenidate hydrochloride, a central nervous system stimulant.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2015-04-17T00:00:00.000Z","mah":"RHODES PHARMS","brand_name_local":null,"application_number":"NDA205831"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}